Browsing by Author "Swagat Tripathy"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Cosmetics: Regulatory Scenario in USA, EU and India
    (Chitkara University Publications, 2015-11-17) Dhull K; Swagat Tripathy; Harish Dureja
    The efficacy, safety, regulatory framework, and marketing of cosmetic products are the most important factors for the growth of the cosmetic industry. The safety of cosmetic goods is regulated by diverse regulatory bodies around the globe who all have their own rules and regulations. The regulations of cosmetics like, nomenclature, labeling, and safety of colorants(s) alter in different countries. Much stringent legislation exists in the European Union (EU) and The United States of America (USA) has very much stringent legislation in order to regulate the use of cosmetic products. The safety assessments of cosmetic products are affected by the different regulations of different regulatory bodies. Nevertheless, there is a need for harmonized regulations throughout the world. An attempt has been made in the present manuscript to compare the current regulatory scenario of cosmetics in the USA, EU, and India.
  • No Thumbnail Available
    Item
    Panoramic View on Quality by Design
    (Chitkara University Publications, 2014-11-30) Manisha; Swagat Tripathy; Harish Dureja
    Quality by design (QbD) is an essential tool in pharmaceutical environment for having product/process/method impregnated with quality. Now, QbD is the greatest solution to construct quality in all pharmaceutical products, while in the same time making it as a part of system is also a key challenge for Industry. For understanding of QbD, it is very much essential to understand the desire product performance profile [Target product Profile (TPP), Target Product Quality Profile (TPQP)] and identify critical quality attributed (CQA). Basically, for meeting the product attributes, the product formulation and process can be designed on the basis of these stated parameters. Nonetheless, this helps in recognizing the effect of raw materials, critical material attributes (CMA), critical process parameters (CPP) on the CQAs and identification and control sources of variability. The in and out understanding for QbD in generic pharmaceutical industry is really vital, because now and then FDA is taking firm stand to make mandatory “deadline” for inclusion of QbD. Therefore, an attempt has been made to highlight quality by design for generic drugs and its implications to pharmaceutical industry.